Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00374907 · ClinicalTrials.gov registry record · Phase 3
A Study Assessing Saxagliptin Treatment in Subjects With Type 2 Diabetes Who Are Not Controlled With Diet and Exercise
A Phase 3 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 3
- Development phase
- 156
- Enrollment target
NCT00374907 is a Phase 3 study that has completed, run by AstraZeneca. The registered enrollment target is 156 participants.
The verdict
NCT00374907, a Phase 3 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 156 participants
- Enrollment target
Study Summary
The purpose of this clinical research study is to learn whether Saxagliptin can improve the body's ability to make its own insulin and lower blood sugar in people with type 2 diabetes
Interventions
- DRUG Placebo
- DRUG Saxagliptin
- DRUG Metformin (open-label)
- DRUG Metformin (blinded)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 156 participants |
| Start Date | 2006-09 |
| Est. Completion | 2009-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00374907
The ClinicalTrials.gov registry entry for NCT00374907 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 156 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT00374907 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00374907 about?
NCT00374907 is a clinical study titled "A Study Assessing Saxagliptin Treatment in Subjects With Type 2 Diabetes Who Are Not Controlled With Diet and Exercise". The purpose of this clinical research study is to learn whether Saxagliptin can improve the body's ability to make its own insulin and lower blood sugar in people with type 2 diabetes
What is the current status of trial NCT00374907?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 156 participants. The study started on 2006-09. Estimated completion is 2009-12.
What interventions are being tested in trial NCT00374907?
The interventions under investigation include: Placebo (DRUG), Saxagliptin (DRUG), Metformin (open-label) (DRUG), Metformin (blinded) (DRUG).
Who is sponsoring clinical trial NCT00374907?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.